Who are we?
Caldan Therapeutics discovers novel therapeutics for metabolic diseases including Type 2 Diabetes and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases
Programs
Caldan Therapeutics initial focus is on activators of free fatty acid receptors implicated in Type 2 Diabetes drawing on its experience of GPCR targets
Meet the Team
Caldan Therapeutics’ founders and management team has strong academic expertise combined with broad experience in GPCR drug discovery and development
Find Us On
